Hair loss treatment statistics: what the FDA labels and the actual trials measured

You have one tab open promising that finasteride will regrow your hair. Another tab is a forum thread saying the same drug ruined someone's life. Both pages quote a percentage, and neither tells you what was counted, where it was counted, or what happened in the placebo group.

That is a terrible way to make a medical decision. You are not asking for marketing copy. You are asking whether a treatment can change what you see in the mirror, and how much uncertainty comes with it.

Here is the honest answer: the best-known trials found measurable differences in fixed scalp areas, over defined periods, against placebo. They did not measure whether you looked better in ordinary life. This page puts those endpoints back in view, so you can read claims without letting hype or horror stories do the thinking. See our male hair loss statistics.

Key numbers

• Finasteride evidence base: Three 12-month double-blind, randomized, placebo-controlled studies included 1,879 men aged 18 to 41 with mild to moderate androgenetic alopecia; the FDA-approved Propecia label says population was 88% Caucasian.
• At 12 months: Finasteride showed a 107-hair difference from placebo in a one-inch diameter circle, or 5.1 cm squared; 679 men received finasteride and 672 placebo; see the FDA label.
• At five years: The label reports a 277-hair difference, with 219 men in the finasteride group and 15 in placebo; see the FDA label.
• Minoxidil trial: A 48-week trial included 393 men aged 18 to 49: 157 used 5% solution, 158 used 2% solution, and 78 placebo; read Olsen et al..
• The famous 45%: In that population, 5% topical minoxidil produced 45% more hair regrowth than 2% topical minoxidil at week 48; it was not 45% of men and was not a comparison against placebo; see Olsen et al..

Table of contents

• What does finasteride actually do, in numbers?
• The endpoint table
• What does minoxidil actually do, in numbers?
• The side-effect numbers people misquote in both directions
• Why the numbers in ads never match the numbers in the label
• What none of these numbers tell you
• The bottom line
• Sources

What does finasteride actually do, in numbers?

In the label's studies, finasteride produced a 107-hair advantage over placebo at 12 months, a 138-hair advantage at two years, and a 277-hair advantage at five years, all inside the same one-inch diameter circle.

The 12-month result came from 679 men assigned to finasteride and 672 assigned to placebo, with p<0.001. At two years, the comparison was 433 men versus 47, and the difference was 138 hairs, also p<0.001. At five years, it was 219 men versus 15, with a 277-hair difference and p<0.001.

The five-year gap partly reflects faster placebo decline; maximum improvement over baseline came in the first two years, then hair count slowly declined but stayed above baseline through five years.

Men who switched from placebo to finasteride after 12 months, a group of 425, gained 56 hairs above their original baseline after one year of treatment. Men randomized to finasteride from the start gained 91 hairs over the same kind of comparison. Caveat: this controlled measurement is not a personal cosmetic forecast.

The endpoint table

The trials counted hairs in a one-inch circle. They never measured whether you look better. Fixed-area counts are repeatable, not a complete answer to a mirror question.

Our Norwood scale guide is more useful than pretending one small circle represents your entire appearance.

Photo: Altan KENDİRCİ on Pexels

What does minoxidil actually do, in numbers?

The Olsen 2002 trial found that 5% topical minoxidil was superior to 2% topical minoxidil and placebo after 48 weeks: 45% more hair regrowth than 2% at week 48—not men's share.

This was a 48-week, double-blind, placebo-controlled, randomized, multicenter trial in 393 men aged 18 to 49 with androgenetic alopecia. The groups were 157 men using 5% solution, 158 using 2% solution, and 78 using placebo; participants applied the solution twice daily.

Researchers evaluated target-area hair counts and scalp coverage; the authors reported more pruritus and local irritation with 5% than 2%. See does minoxidil work for hair loss: ask what endpoint moved, comparator, and period.

Caveat: this result is not your response or an outcome beyond 48 weeks; 5% does not guarantee cosmetic improvement.

The side-effect numbers people misquote in both directions

The label's year-one figures show sexual adverse experiences more often with finasteride than placebo; individual rates were low. You need both columns.

Among 945 men taking finasteride and 934 taking placebo, drug-related decreased libido was 1.8% versus 1.3%; erectile dysfunction was 1.3% versus 0.7%; ejaculation disorder was 1.2% versus 0.7%. Discontinuation due to drug-related sexual adverse experiences was 1.2% versus 0.9%.

Across those listed experiences, 36 of 945 finasteride users, or 3.8%, reported one or more, compared with 20 of 934 placebo users, or 2.1%, with p=0.04. Separately, 1.4% of finasteride users discontinued because of adverse experiences considered possibly, probably, or definitely drug-related, compared with 1.6% of placebo users. The label says the incidence of each listed sexual adverse experience fell to 0.3% or less by the fifth year of treatment.

The same label carries a warning from the seven-year Prostate Cancer Prevention Trial: among men aged 55 and over taking finasteride 5 mg per day, five times the hair-loss dose, the reported risk of Gleason score 8-10 prostate cancer was 1.8% on finasteride versus 1.1% on placebo. This is not the hair-loss-dose trial; keep dose context.

Do not minimize or inflate: trial rates are not automatically ordinary-use rates. A clinician should guide prescriptions; our finasteride side-effects guide can help you prepare questions.

Caveat: these are reported, classified study events; they cannot establish what caused your symptom.

Why the numbers in ads never match the numbers in the label

Finasteride's evidence came from men aged 18 to 41 with mild to moderate androgenetic alopecia; the label says 88% Caucasian. Olsen enrolled men aged 18 to 49.

A proxy is a measurable stand-in: fixed-area hair count is repeatable; looking better across hairline, crown, face, haircut, lighting, and styling is a larger judgment these trials did not measure.

A treatment-placebo difference is not improvement from baseline; the five-year comparison widened partly because placebo declined faster.

When you see a hair-loss statistic, ask:

• Measured over what area? A target circle and whole scalp are different claims.
• For how long? Twelve months, two years, five years, and 48 weeks answer different questions.
• Against what? Placebo, another concentration, or the person's baseline?

Photo: Towfiqu barbhuiya on Pexels

What none of these numbers tell you

No label predicts your cosmetic threshold. It cannot tell you whether your existing receding hairline will frame your face better, whether a different hairstyle matters more, or how you weigh inconvenience against uncertainty.

Hair loss has real medicine behind it, but the internet is dishonest in both directions. Feeling anxious about it does not make you vain; use a baseline photo, careful endpoint reading, and a clinician's advice.

creatine and hair loss, rosemary oil, and surgery need their own evidence.

Caveat: if a result was not measured in the cited label or trial, we will not manufacture certainty for it.

The bottom line

Finasteride's strongest label evidence is a 107-hair difference from placebo at 12 months inside a one-inch diameter circle, widening to 138 hairs at two years and 277 hairs at five years. Minoxidil's famous 45% is more hair regrowth with 5% than 2% at week 48, not 45% of men. Side-effect claims need placebo and dose context.

Real World Appeal covers the missing axis: first-glance perception of a man's presentation on a 70-155 perception axis. test your first impression and see the result before deciding; there is no paywall on your result. It cannot prescribe or replace a clinician or controlled endpoint; it can separate hair anxiety from broader impression.

Sources

• U.S. Food and Drug Administration. Propecia (finasteride) 1 mg prescribing information. DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f904709-65aa-44ce-b144-b4c8a0416e36
• Olsen, E. A., Dunlap, F. E., Funicella, T., Koperski, J. A., Swinehart, J. M., Tschen, E. H., & Trancik, R. J. (2002). A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. Journal of the American Academy of Dermatology, 47(3), 377-385. PMID 12196747. https://pubmed.ncbi.nlm.nih.gov/12196747/
• DailyMed. National Library of Medicine. Label index. https://dailymed.nlm.nih.gov/dailymed/